Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas

  • Eve Maubec
    Assistance Publique–Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
  • Marouane Boubaya
    Assistance Publique–Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
  • Peter Petrow
    Association de Cabinet de Radiologie et d’Imagérie Médicale, Service de Radiologie, Polyclinique Saint-Côme, Compiègne, France
  • Marie Beylot-Barry
    Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
  • Nicole Basset-Seguin
    Assistance Publique–Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France
  • Lydia Deschamps
    Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris, France
  • Jean-Jacques Grob
    Hôpital de la Timone, Marseille, France
  • Brigitte Dréno
    Service Oncodermatologie, Centre Hospitalier Universitaire Nantes, Centre d’Investigation Clinique 1413, Centre de Recherche en Cancérologie et Immunologie Nantes Angers, Université de Nantes, Nantes, France
  • Isabelle Scheer-Senyarich
    Assistance Publique–Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
  • Coralie Bloch-Queyrat
    Assistance Publique–Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
  • Marie-Thérèse Leccia
    Centre Hospitalier Universitaire de Grenoble, Genoble, France
  • Andreea Stefan
    Centre Hospitalier Universitaire de Caen, Caen, France
  • Philippe Saiag
    Assistance Publique–Hôpitaux de Paris, Hôpital Ambroise-Paré, Boulogne, France
  • Florent Grange
    Centre Hospitalier Universitaire Reims, Hôpital Robert-Debré, Reims, France
  • Nicolas Meyer
    Institut Universitaire du Cancer and Centre Hospitalier Universitaire de Toulouse, Toulouse, France
  • Julie de Quatrebarbes
    Centre Hospitalier Genevois, Pringy, France
  • Monica Dinulescu
    Centre Eugène-Marquis, Rennes, France
  • Delphine Legoupil
    Centre Hospitalier Régional Universitaire de Brest, Brest, France
  • Laurent Machet
    Centre Hospitalier Régional Universitaire de Tours, Chambray-les-Tours, France
  • Olivier Dereure
    Université de Montpellier, Montpellier, France
  • Ouidad Zehou
    Assistance Publique–Hôpitaux de Paris, Hôpital Henri-Mondor, Créteil, France
  • Henri Montaudié
    Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, Nice, France
  • Ewa Wierzbicka-Hainaut
    Centre Hospitalier Universitaire La Milétrie, Poitiers, France
  • Yannick Le Corre
    Centre Hospitalier Universitaire d'Angers, Angers, France
  • Sandrine Mansard
    Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, Clermont-Ferrand, France
  • Sarah Guégan
    Assistance Publique–Hôpitaux de Paris, Hôpital Cochin, Paris, France
  • Jean-Philippe Arnault
    Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France
  • Sophie Dalac
    Centre Hospitalier Universitaire de Dijon, Dijon, France
  • François Aubin
    Centre Hospitalier Régional Universitaire Besançon, France
  • Céline Alloux
    Assistance Publique–Hôpitaux de Paris, Agence Générale des Equipements et Produits de Santé, Paris, France
  • Isabelle Lopez
    Association de Cabinet de Radiologie et d’Imagérie Médicale, Service de Radiologie, Polyclinique Saint-Côme, Compiègne, France
  • Soufian Cherbal
    Assistance Publique–Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
  • Annick Tibi
    Assistance Publique–Hôpitaux de Paris, Agence Générale des Equipements et Produits de Santé, Paris, France
  • Vincent Lévy
    Assistance Publique–Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France

抄録

<jats:sec><jats:title>PURPOSE</jats:title><jats:p> To evaluate first-line pembrolizumab monotherapy efficacy and safety in patients with unresectable cutaneous squamous cell carcinomas (CSCCs). </jats:p></jats:sec><jats:sec><jats:title>PATIENTS AND METHODS</jats:title><jats:p> Patients, predominantly men, with their CSSCs’ immunohistochemically determined programmed cell death-ligand 1 (PD-L1) status determined (tumor proportion score threshold, 1%), received pembrolizumab (200 mg every 3 weeks). The primary endpoint was the 39-patient primary cohort’s objective response rate at week 15 (ORR<jats:sub>W15</jats:sub>). Secondary objectives were best ORR, overall survival (OS), progression-free survival (PFS), duration of response (DOR), safety, ORR according to PD-L1 status and health-related quality of life using Functional Assessment of Cancer Therapy–General (FACT-G) score. An 18-patient expansion cohort, recruited to power the study to evaluate the ORR<jats:sub>W15</jats:sub> difference between PD-L1+ and PD-L1– patients, was assessed for ORR, disease control rate, and safety, but not survival. </jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p> Median age of all patients was 79 years. The primary cohort’s ORR<jats:sub>W15</jats:sub> was 41% (95% CI, 26% to 58%), including 13 partial and 3 complete responses. Best responses were 8 partial and 8 complete responses. At a median follow-up of 22.4 months, respective median PFS, DOR, and OS were 6.7 months, not reached, and 25.3 months, respectively. Pembrolizumab-related adverse events affected 71% of the patients, and 4 (7%) were grade ≥ 3. One death was related to rapid CSCC progression; another resulted from a fatal second aggressive head and neck squamous cell carcinoma diagnosed 15 weeks postinclusion. ORR<jats:sub>W15</jats:sub> for the entire population was 42%; it was significantly higher for PD-L1+ patients (55%) versus PD-L1– patients (17%; P = .02). Responders’ W15 total FACT-G score had improved ( P = .025) compared with nonresponders. </jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p> First-line pembrolizumab monotherapy exhibited promising anti-CSCC activity, with durable responses and manageable safety. PD-L1 positivity appears to be predictive of pembrolizumab efficacy. </jats:p></jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ